Compare Nokia Corp (NOK) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Organon & Co. Common Stock — how do they compare? Nokia Corp trades at $9.34 (market cap $54.48B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Nokia Corp is far larger — about 15.1× Organon & Co. Common Stock's market cap, and Nokia Corp pays the higher dividend (1.74%). Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 65 Days and Organon & Co. Common Stock for 0 Days on average.
| NOK | OGN | |
|---|---|---|
Market Cap | $54.48B | $3.61B |
Volume | 85,996,980 | 1,808,049 |
Sector | Technology | Health |
52-Week High | $16.83 | $13.81 |
52-Week Low | $5.55 | $5.70 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $52.50B | $11.03B |
Dividend Yield | 1.74% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $9.86, down 0.4% on the day, with a bearish technical signal. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89 billion with a net income margin of 3.47%. Recent news highlights partnerships in AI, satellite communications, and network automation, including an expanded collaboration with Microsoft announced on September 17, 2026.
The outlook is cautiously optimistic, supported by strong analyst buy ratings (59.6%) and a consensus price target of $17.50, implying significant upside. Key opportunities include growth in AI and cloud infrastructure demand, while risks involve competitive pressures and inconsistent earnings performance. Cash flow volatility remains a concern, with net cash flow negative in 2025 and 2026.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
